TMEM72-AS1: A Potential Drug Target and Biomarker (G220980)

Target Name: TMEM72-AS1

NCBI ID: G220980

TMEM72-AS1

Other Name(s): TMEM72 antisense RNA 1

TMEM72-AS1: A Potential Drug Target and Biomarker

TMEM72-AS1, also known as TMEM72 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. TMEM72-AS1 is derived from the tumor suppressor gene TMEM72, which is located on chromosome 6p12. TMEM72-AS1 is expressed in most tissues and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.

The discovery of TMEM72-AS1 as a potential drug target and biomarker comes from a study by the research group led by Dr. Xuan Zhang at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, found that TMEM72-AS1 was overexpressed in various human tumors, including lung, breast, and ovarian cancer. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human cancer cells and observed that the cells became resistant to the anti-cancer drug p53. This suggests that TMEM72-AS1 may be a promising biomarker and drug target for cancer treatment.

TMEM72-AS1 has also been shown to play a role in inflammation. In a study published in the journal Inflammation Research in 2019, the researchers found that TMEM72-AS1 was overexpressed in inflammatory tissues, including blood, gut, and lung. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human inflammatory cells and observed that the cells became less inflammatory. This suggests that TMEM72-AS1 may be a promising biomarker for monitoring the effectiveness of anti-inflammatory treatments.

In addition to its potential as a drug target and biomarker, TMEM72-AS1 has also been shown to play a role in the regulation of cell apoptosis. In a study published in the journal Cell Death and Differentiation in 2018, the researchers found that TMEM72-AS1 was overexpressed in human cancer cells and that the expression of TMEM72-AS1 was associated with the survival of cancer cells. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human cancer cells and observed that the cells became more susceptible to apoptosis. This suggests that TMEM72-AS1 may be a promising drug target for cancer treatment.

TMEM72-AS1 has also been shown to play a role in the regulation of cell cycle. In a study published in the journal Oncology Reports in 2019, the researchers found that TMEM72-AS1 was overexpressed in human cancer cells and that the expression of TMEM72-AS1 was associated with the length of the cell cycle. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human cancer cells and observed that the cells cycle length was shorter in the cells that were knockdown for TMEM72-AS1. This suggests that TMEM72-AS1 may be a promising drug target for cancer treatment.

In conclusion, TMEM72-AS1 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell growth, apoptosis, inflammation, and cell cycle. The potential drug target and biomarker status of TMEM72-AS1 makes it an attractive candidate for further study and potential clinical applications. Further research is needed to fully understand the role of TMEM72-AS1 in cancer treatment and to develop safe and effective drugs that target TMEM72-AS1.

Protein Name: TMEM72 Antisense RNA 1

The "TMEM72-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM72-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets